Market
Overview
The
inflammatory bowel disease treatment market is expected to reach USD 19,520
Million by 2030 at 5.50% CAGR during the forecast period 2022-2030.
During
the forecast period, the Inflammatory Bowel Disease Treatment Market is expected to grow at a CAGR of 5.50%. Over the
next few years, the market is likely to increase because ulcerative disease and
Crohn's disease are becoming more common around the world. In the coming years,
the market is expected to grow because more people are using biologics to treat
and because there are strong pipeline drugs like risankizumab, upadacitinib,
tofacitinib, ustekinumab, and others. The COVID-19 pandemic didn't have much
effect on the market in 2020. However, many countries have seen a drop in the
number of people being diagnosed with inflammatory bowel disease because of the
complete lockdown.
Market
Segmentation
The
market is split into two groups based on the diseases they treat: ulcerative
colitis and Crohn's disease.
People
with Crohn's disease are expected to make up the largest part of the market.
This segment is growing because Crohn's disease is becoming more common and
because more people around the world are getting treatment for Crohn's disease.
The
injectables market is expected to grow because of factors like the growing use
of biologics to treat ulcerative colitis and Crohn's disease and the growth of
product approvals for biologics.
The
market has been split by drug class into IL inhibitors, JAK inhibitors, TNF
inhibitors, anti-integrin, ASA drugs, corticosteroids, and others.
The
largest part of the market was made up of TNF inhibitors. Patients of
inflammatory bowel disease can use monoclonal antibodies to target remission
and keep it going. This is helping the segment grow in the market.
Regional
Classification
In
2020, North America led the Inflammatory
Bowel Disease Treatment Market therapy,
with a revenue share of around 60.0%. During the projection period, the area is
anticipated to have profitable growth. High treatment rates, a rise in the
prescription of innovative pharmaceuticals, and improved reimbursement
regulations in the region contribute to market expansion.
In
addition, rising research and development initiatives to produce better
treatment choices, as well as the presence of large pharmaceutical firms in the
area, are likely to drive market expansion throughout the projection period. As
stated by the U.S. National Library of Medicine, there are a total of 730
clinical studies connected to IBD as of October 2019, 268 of which are being
undertaken only in the United States.
Asia-Pacific
is expected to have a higher CAGR because more people are becoming aware of
ulcerative colitis and Crohn's disease there. In addition, more and more drugs
are being approved to treat these diseases.
Industry
News
March
2022 - Pfizer Inc. acquires Arena Pharmaceuticals, a clinical-stage business
developing potential revolutionary treatments for the treatment of a variety of
immuno-inflammatory diseases. This breakthrough assisted the firm in
diversifying its portfolio for a number of immuno-inflammatory disorders,
including ulcerative colitis, Crohn's disease, and others.
Bristol
Myers Squibb announced in May 2021 that the Food and Drug Administration had
authorized Zeposia (ozanimod) for the treatment of people with moderate to
severely active ulcerative colitis.
STELARA
was authorized to treat mild to severely active ulcerative colitis in the EU in
September 2019.
Market
Players
The Inflammatory Bowel Disease Treatment Market Players
are Abbott Laboratories, Valeant Pharmaceuticals International , Novartis AG ,
Janssen Biotech Inc. ,Alkem Laboratories Limited , AbbVie Inc. ,UCB Inc ,
Takeda Pharmaceutical Company Limited ,
Biogen Inc. , Pfizer Inc. , Allergan plc
About
Market Research Future:
At Market
Research Future (MRFR), we enable our customers to unravel the complexity of
various industries through our Cooked Research Report (CRR), Half-Cooked
Research Reports (HCRR), & Consulting Services. MRFR team have supreme
objective to provide the optimum quality market research and intelligence
services to our clients.
Contact us:
Market Research
Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,
5Th Floor,
New York, New
York 10013
United States of
America
+1 628 258 0071
Email: sales@marketresearchfuture.com
0 Comments